secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-10-22T20:15:23+00:00
Accession:  0001193125-26-428938
Event type: debt
Sentiment:  negative
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Karyopharm extends indenture forbearance period again, now to Nov 1, 2026 from Oct 22
--------------------------------------------------------------------------------

- Forbearance Period under the Forbearance Agreement and Limited Waiver to Indentures dated September 10, 2026 now ends 11:59 p.m. Eastern on November 1, 2026, instead of October 22, 2026.
- Extension was made under Section 19 of the Forbearance Agreement by the applicable parties; no other terms or new consideration disclosed.
- Second disclosed extension: prior 8-Ks on September 11, 2026 and October 14, 2026 covered the original agreement and the first push-out of the forbearance date.
- Signing officer: Michael Mano, Executive Vice President, Chief Legal Officer and Secretary; company based in Newton, Massachusetts; stock symbol KPTI on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526428938/0001193125-26-428938-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526428938/d172630d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-428938

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer